Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.50 |
| ▸ | PPARA | Q07869 | 11/20 | 0.47 |
| ▸ | PPARG | P37231 | 9/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | MMP15 | P51511 | 1/20 | 0.37 |
| ▸ | MMP16 | P51512 | 1/20 | 0.37 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246172 | 0.91 | PPARD (0.46) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL1245381 | 0.90 | PPARD (0.48) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL1244055 | 0.88 | PPARD (0.46) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL1245291 | 0.88 | PPARD (0.46) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL1245883 | 0.86 | PPARD (0.53) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL1245339 | 0.86 | PPARD (0.44) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL1246265 | 0.84 | PPARD (0.46) | PPARDPPARAPPARGMMP2 | |
| SCHEMBL3021753 | 0.84 | PPARD (0.48) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL3021757 | 0.84 | PPARD (0.48) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 | |
| SCHEMBL1244159 | 0.83 | PPARD (0.42) | PPARDPPARAPPARGSMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039841-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039841-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.